.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Post-Conference Perspectives: ASCO GU 2021

EP. 1: The First Oral GNRH Receptor Antagonist for Advanced Prostate Cancer

March 8th 2021

Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.

EP. 2: Advanced Prostate Cancer: New Findings From ASCO GU 2021

March 8th 2021

Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.

EP. 3: Risk Factors in Advanced Prostate Cancer

March 9th 2021

Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.

EP. 4: Advanced Prostate Cancer: Remaining Challenges

March 9th 2021

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.